A detailed history of Edgemoor Investment Advisors, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Edgemoor Investment Advisors, Inc. holds 57,005 shares of VRTX stock, worth $23.3 Million. This represents 2.33% of its overall portfolio holdings.

Number of Shares
57,005
Previous 56,882 0.22%
Holding current value
$23.3 Million
Previous $26.7 Million 0.56%
% of portfolio
2.33%
Previous 2.5%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$460.0 - $505.78 $56,580 - $62,210
123 Added 0.22%
57,005 $26.5 Million
Q2 2024

Aug 07, 2024

BUY
$392.81 - $485.53 $137,483 - $169,935
350 Added 0.62%
56,882 $26.7 Million
Q1 2024

May 09, 2024

BUY
$407.69 - $446.08 $61,153 - $66,912
150 Added 0.27%
56,532 $23.6 Million
Q4 2023

Feb 07, 2024

BUY
$343.0 - $410.68 $186,592 - $223,409
544 Added 0.97%
56,382 $22.9 Million
Q3 2023

Nov 09, 2023

BUY
$338.18 - $362.46 $85,897 - $92,064
254 Added 0.46%
55,838 $19.4 Million
Q2 2023

Aug 09, 2023

SELL
$314.42 - $351.91 $87,723 - $98,182
-279 Reduced 0.5%
55,584 $19.6 Million
Q1 2023

May 09, 2023

BUY
$283.23 - $323.1 $97,147 - $110,823
343 Added 0.62%
55,863 $17.6 Million
Q4 2022

Feb 07, 2023

SELL
$285.76 - $321.48 $88,585 - $99,658
-310 Reduced 0.56%
55,520 $16 Million
Q3 2022

Nov 08, 2022

BUY
$273.83 - $305.53 $218,790 - $244,118
799 Added 1.45%
55,830 $16.2 Million
Q2 2022

Aug 04, 2022

SELL
$234.96 - $292.55 $28,665 - $35,691
-122 Reduced 0.22%
55,031 $15.5 Million
Q1 2022

May 12, 2022

BUY
$221.42 - $260.97 $2.4 Million - $2.83 Million
10,825 Added 24.42%
55,153 $14.4 Million
Q4 2021

Feb 09, 2022

BUY
$177.01 - $223.45 $1.71 Million - $2.16 Million
9,654 Added 27.84%
44,328 $9.73 Million
Q3 2021

Nov 02, 2021

BUY
$181.39 - $202.99 $6.29 Million - $7.04 Million
34,674 New
34,674 $6.29 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Edgemoor Investment Advisors, Inc. Portfolio

Follow Edgemoor Investment Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Edgemoor Investment Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Edgemoor Investment Advisors, Inc. with notifications on news.